I. COMMENCED TRADING IN FEBRUARY

Company
(Symbol)#

Date Filed

Date Comm.

Shares/ Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Post-Offering
Market Cap (M)@


INITIAL OFFERINGS

ZymoGenetics
Inc.
(ZGEN)1

9/10

2/1

10S

$12

45.6

Lehman Brothers (co-lead); Merrill Lynch (co-lead); Bear, Stearns Pacific Growth Equities

$120

$547

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Market capitalization calculated is based on the offering price.

1 ZymoGenetics' underwriters have an overallotment option for 1.5M shares.

Total: $120M

Number of IPOs in February: 1

Average value of February IPOs: $120M

Number of IPOs in 2002: 1

Total raised in IPOs in 2002: $128.8M*

Average value of IPOs in 2002: $128.8M*

*Figures include an overallotment option exercised in January as part of a 2001 IPO.

FOLLOW-ON OFFERINGS

Amylin Pharmaceuticals Inc. (AMLN)2

12/14/01

2/12

12.07S

$8

79.8

Goldman Sachs (co-lead); Lehman Brothers (co-lead)

$96.6

$638

Aphton Corp. (APHT)3

1/31/02

2/5

1.345S

$12.70

18.74

UBS Warburg (co-lead); Morgan Keegan (co-lead)

$17.1

$238

Array BioPharma Inc. (ARRY)4

1/23/02

2/13

3.45S

$10

27.2

Lehman Brothers; UBS Warburg; Legg Mason Wood Walker; Thomas Weisel Partners

$34.5

$272

SangStat Medical Corp. (SANG)5

12/28/01

2/5

4.5S

$17.25

25.46

Merrill Lynch (co-lead); JP Morgan H&Q (co-lead); Thomas Weisel Partners; Wells Fargo Securities

$77.63

$439

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Market capitalization calculated is based on the offering price.

2 Amylin's offering includes the underwriters' exercise of an overallotment option for 1.57M shares.

3 Aphton raised about $17.1M in the offering of 1.345M shares pursuant to the company's shelf registration.

4 Array's offering includes the underwriters' overallotment option for 450,000 shares, which was exercised in full.

5 SangStat raised $77.63M in the public offering. The underwriters have an overallotment option for 675,000 shares.

Total: $225.83M

Number of follow-on offerings in February: 4

Average value of February follow-ons: $56.46M

Number of follow-on offerings in 2002: 6

Total raised in follow-ons in 2002: $292.13M

Average value of follow-ons in 2002: $48.69M

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)#*

Date Filed

Shares/
Units (M)

Price Range

Shares
Out (M)

Lead, Other Underwriters

Value (M)


INITIAL OFFERINGS

Aderis Pharmaceuticals
Inc.
(ADPX)1

1/11/02

N/A

N/A

N/A

UBS Warburg (co-lead); CIBC World Markets (co-lead); RBC Capital Markets

$100

AgraQuest Inc. (AGRQ)2

8/3/01

3.5S

$11-13

12.8

Merrill Lynch (co-lead); Stephens (co-lead)

$42

APBiotech (APBI; unit of Nycomed Amersham plc)3

10/3/00

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead); Goldman, Sachs (co-lead); Chase H&Q; Salomon Smith Barney

$291.2

CombiMatrix Corp. (CLMX)4

11/22/00

N/A

N/A

N/A

Salomon Smith Barney (co-lead); JP Morgan (co-lead)

$100

Corcept Therapeutics Inc. (CORT)5

12/21/01

4S

$14-16

23.9

U.S. Bancorp Piper Jaffray (co-lead); CIBC World Markets (co-lead); Thomas Weisel Partners

$60

DiaDexus Inc.
(DDXS)6

11/20/00

7S

$12-14

31.1

Lehman Brothers; CIBC World Markets; Robertson Stephens; Fidelity Capital Markets

$91

DOV Pharmaceutical Inc. (DOVP)7

1/29/02

N/A

N/A

N/A

Lehman Brothers (co-lead); CIBC World Markets (co-lead); Lazard Freres; Fidelity Capital Markets

$86.25

Innovative Drug Delivery Systems Inc. (IDDS)8

1/2/02

N/A

N/A

N/A

Thomas Weisel Partners; Wells Fargo Securities

$69

Protarga Inc. (PRTG)9

12/12/01

N/A

N/A

N/A

UBS Warburg (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

Ribapharm Inc. (RIBA)10

6/15/00

20S

$13-15

150

UBS Warburg (co-lead); CIBC World Markets (co-lead)

$280

ViaCell Inc. (VIAC)11

1/30/02

N/A

N/A

N/A

UBS Warburg; Banc of America Securities; U.S. Bancorp Piper Jaffray

$115

FOLLOW-ON OFFERINGS

Ariad Pharmaceuticals
Inc.
(ARIA)12

1/9/02

3S

$5.28

35.4

N/A

$15.84

BioTransplant Inc. (BTRN)13

12/11/01

5S

$8.10

21.1

N/A

$40.5

Celgene Corp.
(CELG)14

12/21/01

N/A

N/A

75.6

N/A

$500

Cell Pathways Inc. (CLPA)15

2/7/01

N/A

N/A

N/A

N/A

$25

Cepheid Inc. (CPHD)16

12/21/01

N/A

N/A

26.56

N/A

$35

Cerus Corp. (CERS)17

8/13/01

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc. (CGPI)18

10/26/01

0.965S

$8.01

N/A

N/A

$7.7

Cytogen Corp.
(CYTO)19

10/26/01

10S

$2.50

79.8

N/A

$25

Exelixis Inc.
(EXEL)20

7/30/01

N/A

N/A

49.2

N/A

$150

Genaissance
Pharmaceuticals
Inc.
(GNSC)21

10/18/01

N/A

N/A

22.8

N/A

$35

Genaera Corp.
(GENR)22

11/21/01

N/A

N/A

N/A

N/A

$50

Geron Corp.
(GERN)23

1/30/02

N/A

N/A

N/A

N/A

$150

Hollis-Eden
Pharmaceuticals
Inc.
(HEPH)24

2/26/02

3S

$8.71

N/A

N/A

$26.13

InSite Vision Inc.
(AMEX:ISV)25

2/2/01

N/A

N/A

N/A

Ladenburg Thalmann (placement agent)

$40

InterMune Inc.
(ITMN)26

12/21

2.5S

$40.02

30.96

Lehman Brothers (co-lead); Morgan Stanley & Co. (co-lead); JP Morgan Securities; Robertson Stephens; UBS Warburg; Adams Harkness & Hill

$100.1

Myriad Genetics
Inc.
(MYGN)27

11/9/01

N/A

N/A

N/A

N/A

$250

NeoTherapeutics
Inc.
(NEOT)28

1/3/01

N/A

N/A

23.5

N/A

$50

NPS Pharmaceuticals
Inc.
(NPSP)29

1/7/02

N/A

N/A

N/A

N/A

$250

Pharmos Corp.
(PARS)30

2/4/02

N/A

N/A

56.6

N/A

$25

SciClone Pharmaceuticals Inc. (SCLN)31

11/6/01

N/A

N/A

N/A

N/A

$20

Targeted Genetics Corp. (TGEN)32

12/13/01

8.84S

$2.57

N/A

N/A

$22.72

Tularik Inc.
(TLRK)33

8/14/01

N/A

N/A

49.2

N/A

$250

III. WITHDRAWN AND POSTPONED

Company(Symbol/
Proposed
Symbol)#*

Date Filed/Date Pulled

Shares/
Units
(M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)


INITIAL OFFERINGS

NeoGenesis
Inc.
(NGPI)34

11/19
2/11

6.2S

$9-10

26.8

JP Morgan; Bear, Stearns; SG Cowen Securities

$58.9

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; AMEX = American Stock Exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

1 Aderis, formerly Discovery Therapeutics Inc., filed for its IPO to raise $100M. Details were not disclosed.

2 AgraQuest amended its prospectus in January to offer 3.5M shares. The value, $42M, is based on the offering price of $12 per share, the midpoint of the expected price range.

3 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

4 CombiMatrix did not disclose further details.

5 Corcept's offering is for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The value of Corcept's offering, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range.

6 DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

7 DOV filed for an IPO, hoping to raise as much as $86.25M.

8 Innovative Drug Delivery filed for an IPO, hoping to raise as much as $69M.

9 Protarga filed for its IPO with hopes of raising $75M. It did not disclose the number of shares to be offered or the expected price range.

10 Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus in January, raising the number of shares to be offered from 18M to 20M. The value of the offering, $280M, is based on the offering price of $14, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares. In February, the company decided to conduct the IPO on the New York Stock Exchange instead of Nasdaq.

11 ViaCell filed for a $115M IPO. No further details were disclosed.

12 Ariad filed a shelf registration to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M.

13 BioTransplant filed a shelf registration statement to sell up to 5M shares of its common stock. The value of the offering, $40.5M, is based on the Dec. 11 opening stock price of $8.10.

14 Celgene filed a universal shelf registration to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M.

15 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

16 Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants.

17 Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

18 The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01.

19 Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration. It privately placed 3M shares in January.

20 Exelixis filed a shelf registration to sell up to $150M in common stock.

21 Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

22 Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock.

23 Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants.

24 Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price.

25 InSite filed a shelf registration in February 2001 to sell $40M in stock.

26 InterMune filed a shelf registration to offer and sell up to $150M in stock. In February, it said it would offer 2.5M shares, which would raise $90M based on the Feb. 28 closing stock price of $36.31. InterMune's underwriters have an overallotment option for 375,000 shares.

27 Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

28 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M.

29 NPS filed a shelf registration statement to offer and sell up to $250M of common stock, preferred stock and debt securities.

30 Pharmos filed a shelf registration to sell up to $25M of common stock, preferred stock, debt securities and/or warrants.

31 SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering.

32 Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57.

33 Tularik filed to sell up to $250M in common stock and debt securities.

34 NeoGenesis amended its price range in February. The value of the offering was based on a price of $9.50 per share, the midpoint of the expected price range. Later in February, the company withdrew the IPO, citing market conditions.